Wet harvesting of no-carrier-added 211 At from an irradiated 209 Bi target for radiopharmaceutical applications


Journal Article

Astatine-211 is one of the most promising α-emitters for targeted cancer radiotherapy. However, research and clinical trials involving 211At-labeled radiopharmaceuticals have often been impeded due to the irregular and sometimes inconveniently low recovery yields obtained by the currently used dry distillation procedure. Therefore, a wet harvesting procedure isolating 211At from an irradiated 209Bi target was explored. The procedure involves target dissolution in concentrated HNO 3 and extraction of the high oxidation state 211At activity with butyl or isopropyl ether. This method resulted in consistent and nearly quantitative yields. The activity was re-extracted in aqueous phase and applied to NIS6 UVW human glioma cells transfected with cDNA encoding the human sodium/iodide symporter (NIS). The significant and specific uptake of 211At activity by these cells suggests that in the ether phase, high oxidation state 211At is reduced to [ 211At]astatide anion. The synthesis of the first astatinated organic compound derived from wet harvested 211At, 3-astatobenzoic acid (ABA), was achieved.

Full Text

Duke Authors

Cited Authors

  • Yordanov, AT; Pozzi, O; Carlin, S; Akabani, G; Wieland, B; Zalutsky, MR

Published Date

  • December 1, 2004

Published In

Volume / Issue

  • 262 / 3

Start / End Page

  • 593 - 599

International Standard Serial Number (ISSN)

  • 0236-5731

Digital Object Identifier (DOI)

  • 10.1007/s10967-004-0481-z

Citation Source

  • Scopus